List of Excipients in Branded Drug RYONCIL

RYONCIL Excipient Strategy and Commercial Opportunities

Last updated: September 4, 2026

Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy in the United States. Its excipient strategy is driven by cell viability, cryopreservation, infusion tolerability, sterility, and lot-to-lot consistency rather than by conventional small-molecule formulation objectives. The commercial opportunity is concentrated in cryoprotectant reduction, animal-origin-free stabilizers, ready-to-use presentation, closed-system handling, and manufacturing process improvements.

What is Ryoncil and how does its formulation work?

Ryoncil is an allogeneic bone-marrow-derived mesenchymal stromal cell therapy approved for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older.[1] It is administered as an intravenous infusion and is supplied as a cryopreserved cell suspension.

The formulation has two functional excipient categories:

Formulation function	Likely excipient role	Commercial priority
Cryoprotection	Dimethyl sulfoxide, or DMSO, limits ice-crystal damage during freezing	High
Protein stabilization	Human serum albumin supports membrane and protein stability during storage and thawing	High
Osmolality and infusion compatibility	Diluent and administration vehicle support intravenous delivery	Medium
Cell recovery	Post-thaw handling conditions influence viability, aggregation and potency	High
Container compatibility	Vial, closure and transfer materials protect sterility and product quality	High

The FDA prescribing information identifies DMSO and human serum albumin as formulation components. The finished product is a living-cell suspension, so excipients must be assessed through cell viability, identity, potency, sterility, endotoxin, mycoplasma, aggregate formation and post-thaw recovery rather than through chemical assay alone.[1]

What excipients are used in Ryoncil?

Ryoncil uses DMSO as the primary cryoprotectant and human serum albumin as a stabilizing protein component.[1] The product is supplied in a cryopreserved state and requires controlled thawing and administration procedures.

Why DMSO is strategically important

DMSO is widely used for cryopreservation of hematopoietic and cellular therapies. It is effective, familiar to regulators and supported by extensive manufacturing experience. Its disadvantages include:

• Infusion-related nausea, abdominal discomfort, headache, hypertension or hypotension;
• Odor and taste concerns caused by dimethyl sulfide metabolites;
• Potential cardiac, pulmonary or neurologic tolerability concerns in vulnerable patients;
• Need for controlled thawing and prompt administration;
• Possible dose burden when multiple vials are required.

DMSO remains difficult to replace because a substitute must preserve viability after freezing, shipping and thawing while maintaining potency and sterility. A lower-DMSO formulation could improve the treatment experience but would require comparative evidence showing equivalent cell recovery and clinical performance.

Why human serum albumin is strategically important

Human serum albumin can reduce cell adhesion to surfaces, protect cell membranes and provide protein stabilization during freezing and thawing. Its use also creates supply-chain and regulatory considerations:

• Plasma-derived sourcing and supplier qualification;
• Viral safety and adventitious-agent controls;
• Lot variability;
• Global availability;
• Cost and contract-manufacturing dependence;
• Potential preference for recombinant or animal-origin-free alternatives.

Replacing plasma-derived albumin with recombinant human albumin could support a stronger global manufacturing position, but the change would require comparability data. The sponsor would need to show that the substitution does not alter cell phenotype, viability, potency, immunogenicity, aggregation or clinical performance.

What formulation patents protect Ryoncil?

Ryoncil is a biologic cell therapy, not a conventional small-molecule drug. Its protection is therefore expected to rely on a combination of:

1. Cell-product composition claims;
2. Cell source and donor-selection claims;
3. Expansion and culture methods;
4. Cryopreservation compositions;
5. Thawing and administration procedures;
6. Potency assays and release specifications;
7. Treatment methods for graft-versus-host disease;
8. Manufacturing controls and closed-system processing.

Unlike a conventional tablet, the commercial value of an excipient patent for Ryoncil would depend on whether the patent protects a complete product configuration or only a generic cryopreservation mixture. A broad claim covering a specific viable MSC population in a defined cryoprotective composition would have greater strategic value than a claim limited to DMSO and albumin concentrations.

Public FDA approval materials establish the approved product and its clinical use, but they do not by themselves establish the complete patent estate. Patent-number-level conclusions require a current review of U.S. Patent and Trademark Office records, international family members, terminal disclaimers, maintenance fees and litigation filings.

How strong is the Ryoncil patent estate?

The core product position is likely stronger than a stand-alone excipient position because cell identity, manufacturing process and clinical use are interdependent. A competitor may be unable to design around the estate simply by changing DMSO concentration if the competitor still relies on substantially similar donor-derived MSCs, expansion methods or potency characteristics.

Patent layer	Design-around difficulty	Commercial relevance
Defined MSC product	High	Protects the cell therapy itself
Manufacturing and expansion	Medium to high	Can block alternative production routes
Cryopreservation composition	Medium	Creates formulation-specific barriers
DMSO reduction	Medium	Supports improved tolerability and differentiation
Method of treatment	Medium	May constrain use in defined patient populations
Potency and release testing	Medium	Can raise regulatory and technical barriers
Container and administration system	Low to medium	Supports operational differentiation

The strongest competitive position usually comes from overlapping claims. A competitor that avoids one formulation claim may still encounter manufacturing, product-definition or method-of-use claims.

When does Ryoncil lose exclusivity?

Ryoncil received FDA approval in December 2024.[2] Its regulatory exclusivity and patent exclusivity should be analyzed separately.

FDA regulatory exclusivity

Ryoncil is a biologic licensed under a Biologics License Application. The principal U.S. biologic exclusivity framework provides 12 years of reference-product exclusivity from first licensure under the Public Health Service Act, subject to statutory limitations.[3] The approval date is not the same as the final date on which all patent or regulatory barriers expire.

Ryoncil also may benefit from orphan-drug exclusivity if the approved indication qualifies and the relevant designation was granted. Orphan exclusivity generally provides seven years of protection for the same indication, but it does not prevent approval of a different drug or certain follow-on products outside the protected indication.[4]

Patent expiration

Patent expiration dates depend on the individual patent, effective filing date, patent-term adjustment, patent-term extension and terminal disclaimer. A reliable expiration analysis cannot be inferred from the FDA approval date. Cell-therapy sponsors often hold older platform patents that expire before approval and later-filed manufacturing or formulation patents that extend protection beyond the initial product patent.

What is the Orange Book status of Ryoncil?

Ryoncil is regulated as a biologic and is not expected to rely on the FDA Orange Book in the same manner as a conventional small-molecule drug. Biologic reference products and biosimilar pathways are generally tracked through the Purple Book framework rather than Orange Book listing practices.[5]

This distinction matters commercially:

• A conventional Paragraph IV certification is not the principal challenge mechanism for a biologic;
• Biosimilar applicants proceed under the Public Health Service Act;
• Patent disputes may arise through the biologics patent-dispute framework;
• Product-specific formulation patents can still affect launch timing;
• Regulatory interchangeability is a separate determination from biosimilarity.

Which companies are challenging Ryoncil?

No approved biosimilar competitor is identified in the FDA approval materials cited here. Ryoncil competes primarily with alternative clinical approaches, including corticosteroids, ruxolitinib and other immunosuppressive treatments for steroid-refractory acute graft-versus-host disease.

Potential future competitors include:

• Biosimilar or follow-on MSC products;
• Other allogeneic stromal-cell therapies;
• Exosome-based products;
• Donor-derived cellular products;
• Hospital-manufactured investigational cell therapies;
• Treatments that reduce the incidence or severity of graft-versus-host disease.

The competitive threat is likely to emerge first through clinical substitution and procurement pressure rather than through an immediate interchangeable biosimilar launch.

What excipient opportunities exist for Ryoncil?

Low-DMSO or DMSO-free cryopreservation

The highest-value formulation opportunity is a cryopreservation system that reduces or eliminates DMSO while preserving post-thaw potency. Candidate excipient classes include sugars, polyols, amino acids, polymers and combinations of intracellular and extracellular cryoprotectants.

A successful product would need to demonstrate:

• Equivalent or superior viable-cell recovery;
• Preserved immunomodulatory potency;
• Low aggregate formation;
• Stable shipping performance;
• Acceptable thawing time;
• Reduced infusion reactions;
• No new toxicity or immunogenicity signal.

The commercial value is strongest if the formulation supports direct bedside administration without extensive washing.

Recombinant human albumin

Recombinant albumin could reduce dependence on plasma-derived material and simplify global supply qualification. The opportunity is most attractive for manufacturers seeking animal-origin-free or chemically defined production.

The principal barrier is comparability. The excipient change must not alter cell attachment, viability, phenotype, potency or release-test behavior.

Ready-to-use infusion presentations

Ryoncil requires pharmacy and clinical staff to manage a cryopreserved living product. Commercial opportunities include:

• Pre-thawed products with controlled short-term stability;
• Reduced-volume presentations;
• Larger-dose formats;
• Closed-system thawing and transfer devices;
• Integrated temperature-monitoring systems;
• Dose-specific packaging.

These approaches may reduce preparation errors and labor costs. They can also create device, container-closure and process patents that complement the core cell-product estate.

Cell-protective polymers and sugar systems

Trehalose, sucrose, hydroxyethyl starch, polyethylene glycol derivatives and selected amino acids are established areas of cryopreservation research. Their value depends on the specific cell type and process. A formulation that works for hematopoietic stem cells may not preserve MSC potency.

The most defensible opportunity is a composition tied to a defined MSC product, freezing profile, storage period and potency endpoint. Generic claims to a broad list of cryoprotectants are more vulnerable to prior art and design-around strategies.

What manufacturing and intellectual-property barriers affect commercial entry?

The main barriers are not limited to the excipient composition. A competing product would need to establish:

• Consistent donor selection;
• Reliable MSC expansion;
• Controlled population doubling;
• Defined passage limits;
• Genetic and phenotypic stability;
• Validated cryopreservation;
• Sterility and mycoplasma control;
• Potency assays linked to mechanism;
• Scalable fill-finish operations;
• Cold-chain distribution;
• Comparable clinical performance.

For Ryoncil, the manufacturing process is part of the competitive moat. Excipients that improve cell survival but create aggregation, potency drift or container interaction may reduce commercial value.

What generic launch risks exist for Ryoncil?

A conventional generic launch scenario is unlikely because Ryoncil is a biologic cell therapy. The principal future launch scenarios are:

Scenario	Timing risk	Commercial effect
No follow-on entrant during core exclusivity	Low near-term price pressure	Preserves premium pricing
Follow-on MSC with noninfringement position	Medium	Could pressure hospital budgets
Biosimilar with patent settlement	Medium to high	Entry date depends on settlement terms
Competing cell therapy with different biology	Medium	May bypass direct biosimilar standards
Lower-DMSO or ready-to-use product	Medium	Could win on tolerability and workflow
Hospital or academic manufacturing	High regulatory barrier	Limited broad commercial threat

How does Ryoncil compare with conventional biologic products?

Ryoncil has a more complex excipient strategy than a monoclonal antibody because the active ingredient is living cells. For an antibody, excipients primarily protect protein structure and control aggregation. For Ryoncil, excipients affect cell survival, membrane integrity, adhesion, metabolism, potency and infusion tolerability.

That complexity increases development cost but also creates multiple differentiation opportunities. A competitor with a superior cryopreservation system could compete on clinical workflow even without changing the underlying cell type.

Key Takeaways

• Ryoncil is an FDA-approved allogeneic MSC therapy for pediatric steroid-refractory acute graft-versus-host disease.
• DMSO is the central cryoprotectant and human serum albumin is the principal stabilizing protein component identified in the product information.
• The strongest excipient opportunities are lower-DMSO formulations, recombinant albumin, ready-to-use presentations and closed-system handling.
• Cell viability, potency, sterility and post-thaw recovery are more important than conventional excipient compatibility alone.
• Ryoncil is a biologic and should be analyzed through the Purple Book and biologics patent framework rather than a conventional Orange Book and Paragraph IV model.
• Competitive entry is more likely to come from follow-on cell therapies or clinically differentiated products than from a near-term conventional generic.
• The defensible IP position is likely to combine cell composition, manufacturing, cryopreservation, potency and method-of-use claims.
• No reliable patent expiration conclusion should be drawn from the December 2024 approval date alone.

FAQs

Can Ryoncil be reformulated without new clinical studies?

A meaningful change in cryoprotectant or stabilizer would require regulatory comparability data. The scope of clinical evidence would depend on the change, its effect on product quality and the FDA’s assessment of risk.

Is DMSO the main commercial weakness in Ryoncil?

DMSO is the clearest formulation target because of infusion tolerability and operational constraints. It is also technically difficult to replace without reducing cell recovery or potency.

Could recombinant albumin create a differentiated Ryoncil product?

Yes. Recombinant albumin could support animal-origin-free manufacturing and supply-chain simplification, but the formulation would require comparability against the approved product.

Are MSC therapies eligible for biosimilar approval?

A follow-on MSC product would need to satisfy the applicable biologic framework. Demonstrating similarity for a living-cell product may be more complex than demonstrating biosimilarity for a protein biologic because manufacturing differences can affect phenotype and potency.

What is the most valuable excipient patent opportunity?

The strongest opportunity is likely a defined cryopreservation composition linked to a specific MSC product, post-thaw potency profile, storage condition and administration process. Generic claims to DMSO substitutes are more exposed to prior art and design-around strategies.

References

1. U.S. Food and Drug Administration. (2024). Ryoncil (remestemcel-L-rknd) prescribing information.

2. U.S. Food and Drug Administration. (2024, December 18). FDA approves first mesenchymal stromal cell therapy to treat steroid-refractory acute graft-versus-host disease in pediatric patients.

3. Public Health Service Act, 42 U.S.C. § 262(k)(7).

4. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.